Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bausch & Lomb Inc.

Division of Valeant Pharmaceuticals International Inc.
www.bausch.com

Latest From Bausch & Lomb Inc.

Keeping Track Of CRLs: US FDA Again Faults Bausch + Lomb Manufacturing

A look at recent developments tracked by the Complete Response Letters chart on the Pink Sheet's US FDA Performance Tracker.

Complete Response Letters Regulation

Keeping Track: Zelboraf Takes Breakthrough Path For Rare Blood Disease; Teva Resubmits Generic EpiPen

The latest drug development news and highlights from our US FDA Performance Tracker.

Approvals Regulation

Valeant Sees Sunshine On Cloudy Day, But Dermatology Recovery Just Starting

The Bausch & Lomb and Salix units are gaining sales momentum, execs said, while debt-reduction efforts remain ahead of schedule. They offered no excuses for a declining dermatology franchise, however.

Sales & Earnings Business Strategies

FDA's Off-Patent, Off-Exclusivity List Draws Few Takers Early On

US agency has received 'very few' inquiries about the drugs on the list since its release.

FDA Generic Drugs
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register